Tirzepatide Weight Loss Medicine Review

Obesity is one of the most common health issues worldwide. Approximately 650 million adults all over the world fall in to the category of obese. Obesity is associated with developing of cardiovascular diseases, diabetes, obstructive sleep apnea and many other health conditions. Thus, if obese, weight loss can have lots of benefits. There are multiple approaches that one can choose to lose weight. The most traditional way include workouts for losing weight as well as wide range of diet plans that promote weight loss. The third category that are usually reserved for the obese people who has health issues and are unable to achieve weight loss by the earlier two methods are weight loss medicine. Tirzepatide is the new weight loss medicine where clinical trails of the same have shown promising results.

What is Tirzepatide?

Tirzepatide is a peptide molecule originally developed for the treatment of Type-2 Diabetes Mellitus. The mechanism of action of Tirzepatide involves dual glucose-dependent insulinotropic polypeptide  (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonism. Stimulation of GIP and GLP-1 receptors are associated with increase in insulin release and inhibition of glucagon release which in turn results in decreasing the blood sugar level – the desirable effect in diabetics. However, it has been found that stimulating both the GIP and GLP-1 together results in weight loss in individuals receiving the medication.

Does Tirzepatide Really Work for weight loss?

A study recently published titled “Tirzepatide Once Weekly for the Treatment of Obesity” has found the drug to be effective for weight loss. In fact it has been found to perform better than Semaglutide for weight loss. The trail reported major weight loss of around 15% to 20.9% from the weight at the time of enrolment over a period of 72 weeks with the medication given subcutaneously, once a week. The median weight of the participant was 104.8 kg with a BMI of 38. As such the reported weight loss ranged from 16.1 kg to 23.6 kg. The dose of Tirzepatide used in the trial were 5mg, 10mg and 15mg. While 5mg weekly dose produced the lowest weight loss of 16.1 kg, 15 mg weekly dose resulted in maximum weight loss of 23.6 kg. It is to be noted 10 mg weekly dose of Tirzepatide produced weight loss of 22.2 kg, which was just slightly lower than the max dose of Tirzepatide used in the study and is thus a promising dose to be used in future for the purpose of treating obesity.

Are there any side effects of Tirzepatide?

Like any other drug, Tirzepatide is no exception when it comes to having side effects.During the 72 week period of the trial some severe side effects have been reported. Although dreadful side effects are reported as we shall see below, most commonly reported side effects are mild, which includes:

• Nausea
• Constipation
• Abdominal Pain
• Diarrhea
• Headache
• Alopecia
• Dizziness
• Dyspepsia
• Decreased Appetite

Few major or severe side effects of Tirzepatide that has been reported include:

• Hepatic Dysfunction
• Renal Dysfunction
• Pancreatitis
• Cancer
• Gall Bladder related disored
• Hypersensitivity
• Low Blood Sugar.

Under what brand name Tirzepatide is sold?

Tirzepatide is manufactured and marketed by Lilly and is sold under the brand name Mounjaro. Mounjaro is available for doses ranging from 2.5 mg to 15 mg per 0.5mL of the drug. It is administered once weekly subcutaneously. Currently Mounjaro is used only to treat Type-2 Diabetes Mellitus.

As Mounjaro or Tirzepatide is reported to cause cancer, most commonly thyroid cancer, while on medication one must look out for swelling or lump in the neck, hoarseness of voice, difficulty in breathing or difficulty in swallowing. In case anyone develops such symptoms, the medication must be stopped and a physician should be contacted immediately. In view of thyroid cancer the manufacturer of Mounjaro warns that it should not be used if there is any family history of thyroid cancer or multiple endocrine neoplasia or if the individual is allergic to any component of Tirzepatide.

Where to buy Tirzepatide Online?

Tirzepatide is current not FDA approved for use in obesity. As of now, Tirzepatide or Mounjaro is only FDA approved for use in Type-2 Diabetes mellitus. Whether or when FDA will approve Tirzepadite for Obesity we do not know yet. Talking about where can you buy Tirzepatide online, as of writing this the drug can be procured online only for research purpose and is not available for individuals. Being a prescription based drug, the medication can procured offline only if its prescribed for Type 2 Diabetes Mellitus.

Conclusion

Tirzepatide although looks promising for losing weight, it comes latched with the uncertainty for certain serious side-effects like thyroid cancer. Also, Tirzepatide is yet not approved by FDA for treating obesity. Considering it can lead to thyroid cancer, post marketing study may lead to total ban of the drug for use in Type-2 Diabetes as well if the number of such adverse events increases, but that is too early to say. Although it looks like a magic drug, do not self-prescribe it for weight loss unless advised by physicians.